TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.~* Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.~* Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.~* Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.~* Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.~* Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.~Exclusion Criteria:~* Has been permanently discontinued from study treatment in the parent study for any reason.~* Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.~* Pregnant or breastfeeding woman.~* Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A : ruxolitinib cream (Type: EXPERIMENTAL): Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
- Cohort A : Vehicle (Type: PLACEBO_COMPARATOR): Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
- Cohort B : roxolitinib cream (Type: EXPERIMENTAL): Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elevated LDL-Cholesterol~* Essential hypertension~Exclusion Criteria:~* Severe Hypertension~* Prior or known muscular or neuromuscular disease of any type~* A history of cardiovascular disease~* Hypertension or hypercholesterolemia due to secondary causes~* Uncontrolled diabetes or insulin treatment~* Evidence of hepatic or renal disease~Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. age of 18\~70, BMI ≥ 18 kg/m2~2. Female patients must avoid pregnancy~3. Patients who are clinically diagnosed with community-acquired pneumonia (CAP)~4. Chest X-ray shows inflammatory exudation or infiltration image.~5. Patients who used antibacterial agents (excluding quinolones) within 72 hours before~6. The patient's disease condition permits oral administration~Exclusion Criteria:~1. Patients who have any of bronchiectasis and pulmonary disease.~2. Hospitalized within 14 days before enrollment~3. Have a history of allergy to any quinolone or fluoroquinolone antibiotic~4. Patients who suffered uncontrolled mental disorders, epilepsy or central nervous system diseases.~5. Renal, liver insufficiency~6. Malabsorption syndrome or other gastrointestinal diseases~7. Immune system diseases,such as a history of human immunodeficiency virus (HIV) infection,neutropenia or malignant tumor in the blood system or a solid organ, or removal of spleen~8. Steroids longterm use, the dose is at least 20mg of prednisone daily~9. Patients under critical condition.~10. Shows significant abnormality of the cardiac conduction system (CCS) or other abnormalities, or prolonged QTc~11. Have a medical history of prolonged QTc, or require concomitant medication of drugs that will lead to prolongation of QTc~12. Patients who received chemotherapy or anti-tumor therapy within 6 months~13. Alcohol abused or drugs banned~14. Patients who used quinolones within two weeks before enrollment~15. Donated more than 500ml of blood within 3 months~16. co-medication of other antibacterial agents required.~17. by investigators judgement,patient who increase the risk to the subjects or interfere with this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nemonoxacin 750 mg (Type: ACTIVE_COMPARATOR): Nemonoxacin 750 mg 2 tablets.
- Nemonoxacin 500 mg (Type: ACTIVE_COMPARATOR): Nemonoxacin 500 mg 3 tablets
- Levofloxacin 500 mg (Type: ACTIVE_COMPARATOR): Levofloxacin 500 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Completed Study DFA102, including all procedures required at the Study Termination visit, without major protocol deviations~* Male, or female and meets all the following criteria:~  1. Has a negative urine pregnancy test result at Study start(not applicable to hysterectomized females)~ 2. If of childbearing potential must practice and be willing to continue to practice appropriate birth control during the entire duration of the study~* Able to read, understand, and sign the Informed Consent Form (ICF) and if applicable,an Authorization to Use and Disclose Protected Health Information Form, answer the study questionnaires, communicate with the investigator, and understand and comply with protocol requirements~Exclusion Criteria:~* Is expected to require or undergo treatment with any exclusionary medication.~* Is undesirable as a study participant as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): Pramlintide and 1.25mg Metreleptin
- 3 (Type: EXPERIMENTAL): Pramlintide and 2.5mg Metreleptin
- 4 (Type: EXPERIMENTAL): Pramlintide and 5.0mg Metreleptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chlorthalidone in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than 18 years.~2. Calculated glomerular filtration rate (GFR) by 4-component Modification of Diet in Renal Disease (MDRD) formula \< 30 ml/min/1.73m2 but ≥15 mL/min/1.73m2. The hospital laboratory uses isotope dilution mass spectrometry (IDMS) calibrated creatinine and the appropriate formula is used to estimate GFR.~3. Hypertension. This is defined as BP of either ≥130 systolic or ≥80 mmHg by 24-hour ambulatory BP monitoring.~4. Treatment with antihypertensive drugs: This would require the use of at least one antihypertensive drug. One of the drugs should be either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). If these are contraindicated then use of a beta-blocker is required prior to randomization.~Exclusion Criteria:~1. Use of thiazide or thiazide-like drugs in the previous 12 weeks.~2. Use of furosemide in a dose \>200 mg/d.~3. BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP monitoring.~4. Expected to receive renal replacement therapy within the next 3 months.~5. Myocardial infarction, heart failure hospitalization, or stroke ≤3 months prior to randomization.~6. Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable).~7. Known hypersensitivity to thiazide or sulfa drugs.~8. Organ transplant recipient or therapy with immunosuppressive agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chlorthalidone (Type: EXPERIMENTAL): Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women, 18-50 years, inclusive.~* Cyclic abnormal uterine bleeding (heavy or prolonged).~* Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in the first 8 days of menses.~* Minimum of one discrete leiomyoma observable by transvaginal ultrasound.~* Endometrial biopsy without evidence of malignancy or atypical or non-atypical hyperplasia.~Exclusion Criteria:~* History of uterine surgery that would interfere with the study endpoints.~* Known coagulation disorder including bleeding disorder or clotting disorder.~* History of, or current uterine, cervix, ovarian, or breast cancer.~* Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), or total bilirubin two times or greater than the upper limit of normal range.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- UPA 5 mg:Placebo (Type: EXPERIMENTAL): Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
- UPA 10 mg:Placebo (Type: EXPERIMENTAL): UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
- UPA 5 mg:UPA 5 mg (Type: EXPERIMENTAL): UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
- UPA 10 mg:UPA 10 mg (Type: EXPERIMENTAL): UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
- Placebo:UPA 5 mg (Type: EXPERIMENTAL): Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
- Placebo:UPA 10 mg (Type: EXPERIMENTAL): Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 65 years of age~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~* Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures~* Patient must be willing to stay at the study site ≥ 72 hours~Exclusion Criteria:~* Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs~* Patient has a current disease or history of a disease that will impact the study or the patient's well-being~* Patient has used or intends to use any of the medications that are prohibited by the protocol~* Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test~* Patient has taken another investigational drug within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Indomethacin 40 mg TID (Type: EXPERIMENTAL): None
- Indomethacin 40 mg BID (Type: EXPERIMENTAL): None
- Indomethacin 20 mg TID (Type: EXPERIMENTAL): None
- Celecoxib 200 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject ≥ 18 years of age.~* Subject meets DSM-IV criteria for a primary diagnosis of schizophrenia or schizoaffective disorder.~* Subject must be judged by the investigator to be an appropriate candidate for switching current antipsychotic medication due to insufficient efficacy and/or safety or tolerability concerns.~Exclusion Criteria:~* Presence of an Axis I or Axis II disorder other than schizophrenia or schizoaffective disorder that is the primary focus of treatment prior to screening.~* Subject has experienced persistent lack of improvement in psychotic symptoms despite adequate trials (at least 6 weeks at standard doses), of two or more antipsychotic agents in the 12 months prior to screening.~* Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or property. Subject has suicidal ideation at baseline or has attempted suicide within 90 days prior to randomization (even without hospitalization).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lurasidone Open-Label Arm A (Type: EXPERIMENTAL): None
- Lurasidone Open-Label Arm B (Type: EXPERIMENTAL): None
- Lurasidone Open-Label Arm C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent prior to participation~2. Female and male patients = 40 years of age~3. Patients diagnosed with COPD and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and therapeutic plan recommendation~Exclusion criteria:~1. Patients with contraindications according to Spiolto® Respimat® Summary of Product Characteristics (SmPC)~2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months~3. Patients continuing LABA-Inhalative Corticosteroids (ICS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~5. Pregnancy and lactation~6. Patients currently listed for lung transplantation~7. Current participation in any clinical trial or any other non-interventional study of a drug or device

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto® Respimat® (Type: None): consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. 18-75 years old, male or female;~2. Meet the standard of clinical diagnosis of acute drug-induced liver injury, the RUCAM causality scale score is more than or equal to 6 points. If the RUCAM causality scale score is 3-5,the subject needs three liver disease experts to confirm whether he is DILI patient, at least two of three liver disease experts should have the same judgment;~3. The serum ALT is between 3and 20 times ULN, but TBiL is less than or equal to 2 times ULN;~4. Liver biochemical indexes(ALT,AST,ALP,GGT,TBiL,albumin,prothrombin time) abnormalities lasted less than 90 days;~5. Patients can understand the nature of the experiment, the nature of the disease, the characteristic of drugs, related treatment methods and the risk they may need to bear if they participate in the test, and sign the informed consent.~Exclusion criteria:~1. Occurrent liver injury caused by other reasons, such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease etc;~2. Acute liver failure or liver function decompensation patient perform, such as hepatic encephalopathy, ascites, albumin is less than or equal to 35g / L, The international standardized ratio (INR) of thrombin is more than 1.5;~3. Serum creatinine is more than 1.5 times ULN;~4. Severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases;~5. Taking drugs that may affect observation of curative effect of the experimental drug during the study;~6. Allergy or intolerance to experimental drugs;~7. With no ability to express their complaints, such as mental illness and severe neurosis patient;~8. The patient can not cooperate and poor compliance;~9. Pregnant and lactating women or women preparing for pregnancy;~10. The patient participated in other clinical trials in 3 months before entering this study;~11. Using other liver-protective drugs except ursodeoxycholic acid or ademetionine within three days;~12. The researchers believe not suitable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- low dose group (Type: EXPERIMENTAL): Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
- high dose group (Type: EXPERIMENTAL): Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
- positive drug control group (Type: ACTIVE_COMPARATOR): Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete